KZKatharina Zwicklbauer

Katharina Zwicklbauer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Katharina Zwicklbauer has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    EXPRESS: Renal Health in Cats with Feline Infectious Peritonitis treated with GS-441524: Baseline Findings and Longitudinal Effects

    by Celia C de Witt Curtius, Marina L Meli, Aline Crespo Bouzon, Jennifer Wenk, Julia Maria Stachowski, Ilaria Cerchiaro, Benita Pineroli, Stefan Unterer, Sandra Felten, Andrea Major, et al.

    Objectives: GS-441524 is effective against feline infectious peritonitis (FIP), but potential renal toxicity remains debated. Renal health was assessed in cats with FIP undergoing antiviral treatment. Methods: Cats with confirmed FIP (n = 80) receiving oral GS-441524 for 42 days were assessed before (day 1; D1), during (D7, D42), and after treatment (D84, D183). Assessments included urine specific gravity (USG), urine protein:creatinine ratio (UPC), urinary cystatin B (uCysB), urine protein electrophoresis, serum creatinine, urea and symmetric dimethylarginine (SDMA).The term potential renal dysfunction was used for cats fulfilling the following criteria: creatinine >140 µmol/l or SDMA ≥ 18 µg/dl and USG <1.035. Serum amyloid A (SAA) and alpha-1-acid glycoprotein (AGP) were assessed in serum, feline coronavirus (FCoV) RNA in blood and urine (D1–D42). Results: At baseline, 97.5% of cats had creatinine concentrations <140 µmol/l; by D183, 23.8% exceeded this threshold (D1–D183: PD <0.0001). Potential renal dysfunction criteria were met in 2.5% of cats at baseline and 8.8% at D183. In contrast, uCysB was increased in 83.8% of cats at D1 and declined during treatment (D1–D183: PD 100 ng/ml had higher UPC values (PMWU <0.0001). Most cats had elevated AGP and SAA at baseline, which normalised during treatment (D1–D42: PD 0.2) was present in 91.3% on D1 and 3.8% on D183; urine protein electrophoresis at D1 revealed predominantly tubular and mixed patterns. Urine was more frequently FCoV RNA-positive than blood on D1 (68.8%/61.3%), but not on D7 (16.3%/45.0%). Conclusions and relevance: Treatment reversed FIP-associated renal abnormalities and inflammation observed at baseline. A small subset of cats met criteria compatible with potential renal dysfunction during the study. Whether these findings reflect delayed FIP-related renal insults or adverse antiviral effects remains unknown but indicate that treatment should not be extended unnecessarily.


  • Open Access

    Large-cell lymphoma in four cats after successful treatment of feline infectious peritonitis with oral GS-441524: a novel clinical observation

    by Katharina Buchta, Solène M Meunier, Sandra Felten, Katharina Erber, Anja Kipar, Roswitha Dorsch, Anna-M Zuzzi-Krebitz, Katharina Zwicklbauer, Michèle Bergmann, Kaspar Matiasek, et al.

    Case series summary: Fatal feline infectious peritonitis (FIP), caused by feline coronavirus (FCoV), can now be cured with GS-441524. Only a few unexpected clinical and laboratory observations have been reported with treatment, including lymphocytosis, eosinophilia and long-term persistence of abdominal lymphadenomegaly. Yet immune overstimulation associated with FIP might have negative long-term consequences. This report describes four cases of large-cell lymphoma (LCL) arising within 2 years of FIP diagnosis and successful treatment with legally sourced oral GS-441524 (15 mg/kg q24h), representing an incidence of 2.0% (n = 4/202) in a large treatment cohort. At LCL diagnosis, two cats were aged under 2 years, one was aged 8 years and one was aged 13 years. All cats showed weight loss, three had hyporexia and two had chronic vomiting; all tested negative for feline leukaemia virus and feline immunodeficiency virus. LCL was diagnosed by histology (n = 3) or cytology (n = 1) at 81, 365 (n = 2) and 595 days after FIP diagnosis/treatment start. The cats died a median of 15.5 days after LCL diagnosis. Neither a high FCoV viral load nor FCoV antigen, as determined by semi-quantitative RT-PCR and immunohistochemistry, respectively, was detected in any of the available samples. PCR for antigen receptor rearrangements revealed a monoclonal B-cell population in two cats, supporting a diagnosis of large B-cell lymphoma. Relevance and novel information: The incidence of LCL reported here among cats in remission from FIP after legally sourced oral GS-441524 treatment is remarkably high compared with the general feline population. LCL should be considered a potential ‘long-FIP syndrome’ and/or a long-term complication after GS-441524 treatment. The pathogenesis of LCL in this context requires further clarification.


  • Open Access

    Viral Coinfections Potentially Associated with Feline Chronic Gingivostomatitis in Cats with Feline Infectious Peritonitis

    by Jennifer Wenk, Marina L. Meli, Solène M. Meunier, Sandra Felten, Celia C. de Witt Curtius, Aline Crespo Bouzon, Ilaria Cerchiaro, Benita Pineroli, Anja Kipar, Stefan Unterer, et al.

    Feline infectious peritonitis (FIP) is a fatal but now treatable disease in cats caused by feline coronavirus (FCoV). This study prospectively investigated viral coinfections in 100 cats diagnosed with FIP and subsequently treated with oral GS-441524 (Bova UK) and their influence on outcome, focusing on viruses potentially associated with feline chronic gingivostomatitis (FCGS). Cats were tested for feline leukemia virus (FeLV), feline immunodeficiency virus (FIV), feline calicivirus (FCV), feline herpesvirus (FHV), feline foamy virus (FFV), and feline gammaherpesvirus (FcaGHV1). Coinfections were identified at the following frequencies: FCV (27), FFV (22), FHV (6), FIV (4), FcaGHV1 (2), and FeLV (2, both progressive infections). FFV infection was significantly associated with FIV (pF = 0.0021) and FHV (pF = 0.0226) infection. FCGS was present in 25/97 cats with FCV infection being associated with FCGS (pF = 0.0032); no significant associa-tions were found for the other viruses and FCGS. The 42-day oral GS-441524 treatment’s success rate was 94% (five cats died, one relapsed). Coinfections did not significantly influence disease severity or treatment outcome, although the low number of cases for some pathogens warrants further investigation. However, advanced age was associated with treatment failure, potentially due to delayed diagnosis as FIP is considered to be less common in older individuals, or to age-related changes in immune function. In summary, viral coinfections, particularly with FCV, were common and should be considered in the clinical and hygienic management of cats with FIP.


  • Open Access

    Whole blood RNA profiling in cats dissects the host immunological response during recovery from feline infectious peritonitis

    by Katharina Zwicklbauer, Pilar Grassl, Martin Alberer, Laura Kolberg, Nina A. Schweintzger, Sonja Härtle, Kaspar Matiasek, Regina Hofmann-Lehmann, Katrin Hartmann, Caroline C. Friedel, et al.

    Feline infectious peritonitis (FIP) is caused by infection with the feline coronavirus (FCoV) and is fatal if left untreated. In most cats, FCoV primarily infects the gastrointestinal tract and remains asymptomatic or causes only mild enteritis, with only a small proportion of infected cats developing FIP. An excessive and harmful immune response leading to characteristic (pyo)granulomatous phlebitis is believed to play a key role in the development of FIP, along with complex interactions between host and viral factors. Our research group recently demonstrated successful treatment of cats with naturally occurring FIP using the antiviral nucleoside analogue GS-441524. Treatment led to complete recovery without any relapses for a follow-up period of one year, demonstrating both a short- and long-term cure. To investigate differential gene expression and corresponding molecular pathways in cats with FIP before, during, and after antiviral treatment, RNA sequencing was performed on full blood samples of 18 cats treated successfully in a prospective study. Samples were analyzed before treatment, at different timepoints while on treatment with GS-441524 and after completion of treatment. Additionally, gene expression profiles were compared to 12 healthy FCoV-infected control cats and 5 healthy uninfected control cats. The results revealed both a widespread dysregulation of the blood RNA signature in cats with FIP as well as its rapid normalization within the first week of treatment. Significant changes were already apparent within the first two days of treatment. The results of the present study suggest that elimination of the virus from the blood leads to rapid control and subsequent normalization of the damaging immune response, a finding that corresponds well to the clinical response to treatment. This study illustrates the host response to treatment at the molecular level and provides further evidence that a shorter treatment duration than the 84 days predominantly practiced is sufficient.


  • Open Access

    Unexpected Clinical and Laboratory Observations During and After 42-Day Versus 84-Day Treatment with Oral GS-441524 in Cats with Feline Infectious Peritonitis with Effusion

    by Katharina Buchta, Anna-Maria Zuzzi-Krebitz, Michèle Bergmann, Roswitha Dorsch, Katharina Zwicklbauer, Kaspar Matiasek, Regina Hofmann-Lehmann, Marina L. Meli, Andrea M. Spiri, Yury Zablotski, et al.

    The nucleoside analogue GS-441524 is a common treatment for cats with feline infectious peritonitis (FIP). In a previous study, 40 cats with FIP with effusion were treated with 15 mg/kg GS-441524 orally once daily for either 42 days or 84 days, and a 42-day treatment was as effective as the earlier recommended 84-day treatment. The aim of the present study was to describe unexpected clinical and laboratory observations occurring during and after treatment (within one year) in these cats and to compare them regarding the different treatment durations. Thirty-eight cats recovered rapidly during treatment, two cats had to be euthanized, and one cat was lost to follow-up. During treatment, 25 cats developed diarrhea. Lymphocytosis occurred in 26/40 cats during treatment, eosinophilia in 25/40 during treatment, increased alanine aminotransferase activity in 22/40, alkaline phosphatase activity in 7/40, and symmetric dimethylarginine levels in 25/40. These unexpected observations occurred equally in both treatment duration groups, but statistically significantly more cats developed lymphocytosis and eosinophilia when treated for 84 days. Although most of the unexpected observations during GS-441524 treatment improved or disappeared after treatment termination, these conditions have to be monitored, and treatment should not be given for longer than necessary.


  • Open Access

    Myocarditis in Cats with Feline Infectious Peritonitis Can Be Cured with GS-441524 and Symptomatic Cardiovascular Treatment

    by Katharina Buchta, Jana Friederich, Anna-Maria Zuzzi-Krebitz, Jessica Schöbel, Jenny Eberhard, Katharina Zwicklbauer, Andrea M. Spiri, Regina Hofmann-Lehmann, Katrin Hartmann, Gerhard Wess

    Feline infectious peritonitis (FIP) caused by feline coronavirus (FCoV) is a fatal disease in cats characterized by variable manifestations. Myocarditis represents a less commonly described pathology within the clinical spectrum of FIP. No research has described the successful treatment of FIP-induced myocarditis. In this study, 40 cats were included and treated with 15 mg/kg of GS-441524 every 24 h orally. All cats were diagnosed with FIP by reverse transcription quantitative PCR in effusion in combination with typical clinical and laboratory changes. Echocardiography was performed in all cats, and myocarditis was suspected in 4/40 cats. Equivocal wall thickness was diagnosed in 2/4 cats, while systolic dysfunction with biatrial dilation was diagnosed in the other 2/4 cats. One cat also presented with ventricular ectopy. A severe increase in cardiac troponin I was seen in all four cats (median 1.82 ng/mL (1.20–5.84 ng/mL)). Cardiac dimensions and electrocardiographic abnormalities completely normalized in all four cats during treatment with GS-441524 and remained stable after treatment discontinuation during a one-year follow-up period. Myocarditis can be a clinical feature of FIP and present with different cardiologic manifestations. FIP-induced myocarditis can be cured with GS-441524 in combination with symptomatic cardiovascular treatment including pimobendan, clopidogrel, furosemide, or atenolol, depending on the clinical presentation.


  • Open Access

    Structure elucidation and quantification of the active pharmaceutical ingredient in a non-approved drug and in cat serum using QTRAP-MS/MS and ZenoTOF-MS/MS

    by Luke Tu, Jeannie Horak, Daniela Krentz, Katharina Zwicklbauer, Katrin Hartmann, Eveline Lescrinier, Martin Alberer, Ulrich von Both, Berthold Koletzko


  • Die feline infektiöse Peritonitis – ein aktueller Überblick

    by Katharina Zwicklbauer, Michèle Bergmann, Martin Alberer, Ulrich von Both, Katrin Hartmann

    Zusammenfassung: Coronaviren (CoVs) sind positiv einzelsträngige RNA-Viren, die verschiedene Tierarten sowie Menschen infizieren können. Besonders relevant für Katzen ist das feline Coronavirus (FCoV), das in Katzenpopulationen weltweit verbreitet ist. Eine Infektion mit FCoV verläuft in der Regel ohne Symptome. In Mehrkatzenhaushalten entwickeln jedoch etwa 5–12% der FCoV-infizierten Katzen aufgrund von Mutationen im Spike-Gen die feline infektiöse Peritonitis (FIP). FIP ist eine immunvermittelte Erkrankung, die bislang immer tödlich verlief. Die Mutationen führen zu einem Tropismus-Wechsel von Enterozyten zu Monozyten und Makrophagen. Der damit verbundene Wechsel in der Virulenz von FCoV führt zu der charakteristischen granulomatösen Vaskulitis und Perivaskulitis, die bei FIP beobachtet wird. In letzter Zeit gibt es zahlreiche neue Erkenntnisse zur FIP. So zeigen Studien, dass humanmedizinische antivirale Medikamente, wie das Nukleosidanalogon GS-441524, bei FIP wirksam sind und betroffenen Katzen eine Überlebenschance von bis zu 100% bieten. Zudem wurde eine neuartige FCoV-Variante, das FCoV-23, bei Katzen aus Zypern identifiziert. Dieses Virus entstand nach derzeitigem Kenntnisstand durch eine Rekombination zwischen FCoV und dem hochvirulenten pantropischen caninen Coronavirus; es kann direkt von Katze zu Katze übertragen werden und FIP auslösen. Darüber hinaus gibt es immer mehr Hinweise darauf, dass FIP häufig mit einer Myokarditis assoziiert ist. Dieser Artikel bietet einen Überblick über den aktuellen Wissensstand der FIP, unter Berücksichtigung der Pathologie, klinischer Symptome, wirksamer Therapiemöglichkeiten und Präventionsmaßnahmen.


  • Top Cited Papers
    Open Access

    Short Treatment of 42 Days with Oral GS-441524 Results in Equal Efficacy as the Recommended 84-Day Treatment in Cats Suffering from Feline Infectious Peritonitis with Effusion—A Prospective Randomized Controlled Study

    by Anna-M. Zuzzi-Krebitz, Katharina Buchta, Michèle Bergmann, Daniela Krentz, Katharina Zwicklbauer, Roswitha Dorsch, Gerhard Wess, Andrea Fischer, Kaspar Matiasek, Anne Hönl, et al.

    In the past, feline infectious peritonitis (FIP) caused by feline coronavirus (FCoV) was considered fatal. Today, highly efficient drugs, such as GS-441524, can lead to complete remission. The currently recommended treatment duration in the veterinary literature is 84 days. This prospective randomized controlled treatment study aimed to evaluate whether a shorter treatment duration of 42 days with oral GS-441524 obtained from a licensed pharmacy is equally effective compared to the 84-day regimen. Forty cats with FIP with effusion were prospectively included and randomized to receive 15 mg/kg of GS-441524 orally every 24h (q24h), for either 42 or 84 days. Cats were followed for 168 days after treatment initiation. With the exception of two cats that died during the treatment, 38 cats (19 in short, 19 in long treatment group) recovered with rapid improvement of clinical and laboratory parameters as well as a remarkable reduction in viral loads in blood and effusion. Orally administered GS-441524 given as a short treatment was highly effective in curing FIP without causing serious adverse effects. All cats that completed the short treatment course successfully were still in complete remission on day 168. Therefore, a shorter treatment duration of 42 days GS-441524 15 mg/kg can be considered equally effective.


  • Open Access

    Adapting the SMART tube technology for flow cytometry in feline full blood samples

    by Katharina Zwicklbauer, Dominik von la Roche, Daniela Krentz, Laura Kolberg, Martin Alberer, Yury Zablotski, Katrin Hartmann, Ulrich von Both, Sonja Härtle, Sonja H

    Flow cytometry of blood samples is a very valuable clinical and research tool to monitor the immune response in human patients. Furthermore, it has been successfully applied in cats, such as for infections with feline immune deficiency virus (FIV). However, if cells are not isolated and frozen, analysis of anticoagulated blood samples requires mostly prompt processing following blood collection, making later analysis of stored full blood samples obtained in clinical studies often impossible. The SMART Tube system (SMART TUBE Inc., California, United States; SMT) allows fixation and long-term preservation of whole blood samples at −80°C. However, this system has so far only been applied to human biological samples. In the present study, a new flow cytometry SMART Tube protocol adapted for feline whole blood samples was successfully established allowing quantification of T-helper cells, cytotoxic T-cells, B-cells, monocytes, and neutrophils up to 2 years post sampling. Results obtained from frozen stabilized and fresh blood samples were compared for validation purposes and correlated to differential blood counts from a conventional hematology analyzer. Clinical applicability of the new technique was verified by using samples from a treatment study for feline infectious peritonitis (FIP). Using the new SMT protocol on retained samples, it could be demonstrated that long-term storage of these SMT tubes is also possible. In summary, the newly adapted SMT protocol proved suitable for performing flow cytometry analysis on stored feline whole blood samples, thus opening up new avenues for veterinary research on a variety of aspects of clinical interest.